ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0008509 | A method for diagnosis of fetal diseases by sampling the cells of the placental chorionic villi for DNA analysis, presence of bacteria, concentration of metabolites, etc. The advantage over amniocentesis is that the procedure can be carried out in the first trimester. | CVS - Chorionic villus sampling|chorionic villus sampling|chorionic villi biopsy|Chorionic villus sampling|Chorionic Villi Biopsy|Chorionic Villi Sampling|Sampling of chorionic villus (procedure)|Samplings, Chorionic Villi|Samplings, Chorionic Villus|Chorionic Villi Samplings|Sampling of chorionic villus|CVS|Sampling, Chorionic Villus|Chorionic Villi Biopsies|Chorionic Villus Sampling|Biopsies, Chorionic Villi|Biopsy, Chorionic Villi|chorionic villus sampling (CVS)|Chorionic Villus Samplings|chorionic villi sampling|Sampling, Chorionic Villi|CVB - Chorionic villus biopsy | Chorionic Villi Sampling |
C0017473 | null | Germ Lines|germ line | Germ Line |
C0085872 | A layer of extracellular matrix found beneath epithelial tissues. It is secreted by epithelial cells and comprised of proteoglycans, laminin and type IV collagen. | basal lamina|Basal Laminas|basement lamina|Lamina, Basal|Basement Laminas|Laminas, Basement|Lamina Densa|Basal lamina of connective tissue|Basal lamina|Basal lamina, NOS|Lamina, Basement|Laminas, Basal|Basal Lamina|Basement Lamina|External lamina | Basal lamina |
C0019829 | A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. | Lymphogranulomatosis, malignant|Hodgkin granuloma [obs]|Malignant Granulomas|hodgkins disease|lymphogranulomatosis (malignant)|Hodgkin's lymphoma|Hodgkin's granuloma (disorder)|hodgkin lymphomas|Lymphogranuloma, Malignant|Hodgkins Paragranuloma|HL|Hodgkin's disease|Granuloma, Hodgkin's|Hodgkin lymphoma, no ICD-O subtype|hodgkin's lymphomas|Lymphogranuloma, malignant|Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype|Hodgkin sarcoma [obs]|Hodgkin's granuloma|Hodgkin's disease, NOS|Malignant lymphoma, Hodgkin's type|Hodgkin sarcoma|Hodgkin Lymphoma|Hodgkin's disease (disorder)|HODGKIN LYMPHOMA|Granuloma, Hodgkin|Lymphoma, Hodgkins|Hodgkin's sarcoma (clinical)|Hodgkin granuloma [obs] (morphologic abnormality)|Hodgkin's Paragranuloma|HD|Hodgkins Disease|hodgkin's lymphoma|hodgkins diseases|Hodgkin's sarcoma (disorder)|Granuloma, Hodgkins|Malignant lymphogranulomatosis|Hodgkin sarcoma [obs] (morphologic abnormality)|Hodgkins Granuloma|Malignant lymphoma, Hodgkin's|Malignant Lymphogranulomas|HD - Hodgkin's disease|HODGKIN'S DISEASE|Malignant Lymphogranuloma|Hodgkin's disease, unspecified type|Hodgkin's paragranuloma, NOS|Hodgkin Granuloma|hodgkins lymphoma|HODGKIN DISEASE|Hodgkin lymphoma, NOS|hodgkins lymphomas|CHL|HODGINS|Hodgkin's Lymphoma|hodgkin disease (HD)|HODGKINS DISEASE SYSTEMIC|Hodgkin's granuloma (clinical)|Lymphoma, Hodgkin|Hodgkin's Granuloma|Lymphoma, Hodgkin's|Disease, Hodgkins|hodgkin lymphoma|hd|Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Hodgkin's paragranuloma (clinical)|Disease, Hodgkin|Lymphogranulomas, Malignant|Hodgkin`s disease|hodgkin's disease|Hodgkin granuloma|Hodgkin's disease (clinical)|Hodgkin Disease|Disease, Hodgkin's|Hodgkin's Disease|Hodgkin's sarcoma|Hodgkin lymphoma|Hodgkins disease|LYMPHOMA, HODGKIN, CLASSIC|Hodgkin's lymphoma NOS|Hodgkin disease|hodgkin's lymphoma disease|lymphogranulomatosis|hodgkin disease|Hodgkin's paragranuloma, nodular|Malignant Hodgkin's lymphoma|Malignant Granuloma|Hodgkin's paragranuloma|Granuloma, Malignant|Hodgkin's disease NOS|Hodgkins lymphoma|HODGKINS DISEASE|Hodgkins Lymphoma|Malignant lymphogranuloma | Hodgkin Disease |
C0206180 | A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS. | Anaplastic large cell lymphoma, CD30+|Large-Cell Lymphomas, Anaplastic|Systemic Anaplastic Large Cell Lymphoma|Lymphoma, Anaplastic Large-Cell|Large cell anaplastic lymphoma (disorder)|ki 1 lymphoma|Anaplastic Large Cell Lymphoma|CD30+ Anaplastic Large Cell Lymphoma|Anaplastic Large-Cell Lymphomas|Lymphomas, Ki-1|Anaplastic large cell lymphoma, T cell and Null cell type (morphologic abnormality)|Ki-1 Lymphomas|Anaplastic large-cell lymphoma|ki-1 lymphoma|Anaplastic large cell lymphoma (ALCL) CD30+|Lymphoma, Large-Cell, Anaplastic|Anaplastic Large-Cell Lymphoma|Ki-1+ Anaplastic Large Cell Lymphoma|Large cell (Ki-1+) lymphoma|anaplastic large cell lymphoma|Anaplastic large cell lymphoma|Ki-1 Lymphoma|large cell anaplastic lymphoma|Lymphoma, Ki-1|Lymphoma, Large-Cell, Ki-1|lymphoma, anaplastic large cell|Systemic Anaplastic Large-Cell Lymphoma|Large-Cell Lymphoma, Anaplastic|CD30-Positive Anaplastic Large-Cell Lymphoma|Large cell anaplastic lymphoma|Anaplastic large cell lymphoma, T cell and Null cell type|Lymphomas, Anaplastic Large-Cell|ALCL|Ki-1+ ALCL|Ki 1 Lymphoma|CD30 Positive Anaplastic Large Cell Lymphoma|CD30+ Anaplastic Large-Cell Lymphoma|(Ki-1+) lymphoma | Ki-1+ Anaplastic Large Cell Lymphoma |
C0028908 | Unctuous combustible substances that are liquid or easily liquefiable on warming, and are soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils. Depending on their behavior on heating, they are volatile or fixed. (Dorland, 28th ed) | Oils|oil|Oil-containing product|Oil, NOS|Oil|Product containing oil (product)|Oily|oils|Oil (substance) | Oils |
C0684118 | null | Early erythroblast (cell)|Early erythroblast|early erythroblast | Early erythroblast |
C1257771 | A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of erythroid burst forming cells. | Erythroid Burst Forming Unit|Burst-forming unit erythroid (cell)|BFU-Es|BFU E|BFU-E|Erythroid Burst-Forming Unit|Burst Forming Units, Erythroid|Erythroid Burst-Forming Units|Units, Erythroid Burst-Forming|Burst-forming unit erythroid|Burst-Forming Unit, Erythroid|Burst Forming Unit-Erythroid|BFU-E - Burst-forming unit erythroid|Unit, Erythroid Burst-Forming | Burst-Forming Units, Erythroid |
C0006710 | The calcium salt of the water-soluble vitamin B5, ubiquitously found in plants and animal tissues with antioxidant property. Pentothenate is a component of coenzyme A (CoA) and a part of the vitamin B2 complex. Vitamin B5 is a growth factor and is essential for various metabolic functions, including the metabolism of carbohydrates, proteins, and fatty acids. This vitamin is also involved in the synthesis of cholesterol, lipids, neurotransmitters, steroid hormones, and hemoglobin. | Calcium pantothenate (substance)|beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, Calcium Salt|Pantothenate, Calcium|Vitamin B5, Calcium Salt|Calcium pantothenate|calcium pantothenate|Ca-HOPA|PANTOTHENIC ACID (AS CALCIUM)|Dextro Calcium Pantothenate|CALCIUM PANTOTHENATE|N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-beta-alanine Calcium|Pantothenic Acid Calcium Salt|Calcium Pantothenate|Calcium pantothenate preparation|Calcium D(+)-N-(alpha,gamma-dihydroxy-beta,beta-dimethylbutyryl)-beta-alaninate Calcium, bis(pantothenato)-|Bis(pantothenato)calcium|Pantothenate Calcium|Calcium D-pantothenate | calcium pantothenate |
C0010583 | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide|Cyclophosphamidum|Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester|Cyclophosphamide|Cyclophosphanum|CYT|Cyclophosphamide-containing product|cyclophosphamide|cyt|Cytophosphane|Claphene|2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide, monohydrate|2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide|Syklofosfamid|cyts|N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide|(-)-cyclophosphamide|Mitoxan|CPM|Cyclophosphamid|Ciclofosfamide|(-)-Cyclophosphamide|Cyclophosphamide (substance)|N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide|Ciclofosfamida|N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-Oxide|Cyclophosphane|(RS)-Cyclophosphamide|CTX|Cyclophospham|Product containing cyclophosphamide (medicinal product)|cyclophosphane|(+-)-Cyclophosphamide|Cyclophosphan|CYCLOPHOSPHAMIDE | cyclophosphamide |
C0071126 | An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04) | THP-ADM|(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione|THP-doxorubicin|THP-DOX|4'-O-Tetrahydropyranyl Doxorubicin|Adriamycin, tetrahydropyranyl|THP-Adriamycin|THP-Doxorubicin|4'-O-tetrahydropyranyldoxorubicin|THP-Adm|thepirubicin|5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-|THP-adriamycin|Pirarubicin|[8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione|THP|PIRARUBICIN|pirarubicin|Tetrahydropyranyl-Doxorubicin|4'-O-tetrapyranyldoxorubicin|pirarubicin (THP)|thp|Pirarubicin (substance)|4'-O-tetrahydropyranyladriamycin|Tepirubicin|(2"R)-4'-O-Tetrahydropyranyladriamycin | pirarubicin |
C0218640 | A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. | Glycosylated recombinant granulocyte colony stimulating factor|Glycosylated Recombinant Granulocyte Colony Stimulating Factor|Glycosylated Recombinant G-CSF|Granulocyte colony-stimulating factor lenograstim|Granulocyte colony stimulating factor 3 (CHO cell derived)|lenograstim|Lenograstim-containing product|Lenograstim rDNA|LENOGRASTIM|Product containing lenograstim (medicinal product)|Glycosylated Recombinant Granulocyte Colony-Stimulating Factor|Glycosylated recombinant G-CSF|Lenograstim (substance)|Lenograstim (genetical recombination)|Lenograstim|G-CSF (CHO cell derived) | lenograstim |
C0218640 | A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. | Glycosylated recombinant granulocyte colony stimulating factor|Glycosylated Recombinant Granulocyte Colony Stimulating Factor|Glycosylated Recombinant G-CSF|Granulocyte colony-stimulating factor lenograstim|Granulocyte colony stimulating factor 3 (CHO cell derived)|lenograstim|Lenograstim-containing product|Lenograstim rDNA|LENOGRASTIM|Product containing lenograstim (medicinal product)|Glycosylated Recombinant Granulocyte Colony-Stimulating Factor|Glycosylated recombinant G-CSF|Lenograstim (substance)|Lenograstim (genetical recombination)|Lenograstim|G-CSF (CHO cell derived) | lenograstim |
C1292777 | A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen. | Aggressive NK-cell leukaemia|Aggressive natural killer-cell leukemia (morphologic abnormality)|Natural Killer Cell Leukemia|NK-Cell Leukemia|Aggressive natural killer-cell leukemia|Aggressive NK-cell leukemia|Aggressive NK cell leukemia|Aggressive NK-Cell Leukemia/Lymphoma|Aggressive natural killer-cell leukemia (disorder)|Aggressive NK cell leukaemia|Aggressive NK-Cell Leukemia|aggressive NK-cell leukemia|Aggressive natural killer-cell leukaemia|NK Cell Leukemia | Aggressive natural killer-cell leukemia |
C0149678 | Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY). | ebv infection|epstein-barr infection virus|epstein-barr virus infection|Human Herpes Virus 4 Infections|Epstein-Barr Virus Infections|Epstein-Barr virus disease (disorder)|barr epstein infections|Infections, EBV|Virus Infection, Epstein-Barr|infection epstein-barr virus|Infection, EBV|Human Herpesvirus 4 Infections|Epstein-Barr virus disease|Virus Infections, Epstein-Barr|EBV INFECTION|Epstein-Barr virus diseases|EBV Infection|infection ebv|Infection, Epstein-Barr Virus|Epstein Barr Virus Infection|EBV Infections|Epstein-Barr virus infection|Epstein-Barr Virus Infection|virus infections barr epstein|Herpesvirus 4 Infections, Human|Infections, Epstein-Barr Virus|epstein barr infection viral|epstein barr virus infection|EPSTEIN BARR VIRUS INFECTION|Epstein Barr Virus Infections|EPSTEIN BARR INFECTION|epstein barr infection | Epstein-Barr Virus Infections |
C0417744 | null | Sting/bite by mosquito|Mosquito bite|Mosquito bite (disorder) | Mosquito bite -- finding |
C1533699 | A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate. | Gemtuzumab ozogamicin (substance)|Gemtuzumab ozogamicin-containing product|GEMTUZUMAB OZOGAMICIN|Gemtuzumab-Ozogamicin|gemtuzumab ozogamicin|hP67.6-Calicheamicin|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin|Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody|Product containing gemtuzumab ozogamicin (medicinal product) | gemtuzumab ozogamicin |
C0600558 | Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment. | neoadjuvant treatment|Neoadjuvant Therapy|Neoadjuvant|Preoperative Therapy|Neoadjuvant Therapies|Neoadjuvant Treatments|Induction Therapy|Therapy, Neoadjuvant|Treatment, Neoadjuvant|Neoadjuvant Treatment|neoadjuvant therapy|Therapies, Neoadjuvant|Treatments, Neoadjuvant|induction therapy | Neoadjuvant Therapy |
C1135161 | Localized primary tumor, as defined for stage 1, 2A, or 2B, with dissemination limited to skin, liver, and/or bone marrow (limited to infants younger than 1 year). Marrow involvement should be minimal (i.e., <10% of total nucleated cells identified as malignant by bone biopsy or by bone marrow aspirate). More extensive bone marrow involvement would be considered stage 4 disease. The results of the MIBG scan, if performed, should be negative for disease in the bone marrow. (cancer.gov) | Neuroblastoma, metastatic (morphologic abnormality)|metastatic neuroblastoma|neuroblastoma, disseminated|Stage 4S Neuroblastoma|special neuroblastoma|neuroblastoma, stage 4S|stage 4S neuroblastoma|Neuroblastoma, metastatic|Pepper's Syndrome|Stage IVS Neuroblastoma|stage IVS neuroblastoma|neuroblastoma, metastatic|Neuroblastoma Stage IVS|disseminated neuroblastoma|neuroblastoma, stage IVS | Stage 4S neuroblastoma |
C0574032 | A method of putting fluids, including drugs, into the bloodstream. | Infusion - action|infusion|Infusion procedures|Infusion Technique|infusions|Infusion technique (qualifier value)|infusion procedure|Infusion, NOS|Infusion|Infusion - action (qualifier value)|Infusion Procedure|Infusion (procedure)|Infusion technique | Infusion procedures |
C0733521 | null | ara c|Ara-C|Ara C|ara C|ARA-C|ara-c | Ara-C |
C0867389 | A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation. | Graft versus host disease, chronic|GVHD, chronic|Chronic graft-versus-host disease (disorder)|Chronic graft-versus-host disease|Chronic Graft Versus Host Disease|Chronic graft versus host disease|Chronic GVHD | Chronic graft-versus-host disease |
C0376544 | A cancer of the blood or bone marrow, such as leukemia or lymphoma. | Malignant Hematopoietic Neoplasm|Hematopoietic Neoplasm|Hematopoietic Malignancies|hematopoietic malignancy|Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Neoplasms including Lymphomas|Hematopoietic neoplasm|hematopoietic neoplasm|Hematopoietic Neoplasms|Hematopoietic Cell Tumor|Malignancy, Hematopoietic|Hematopoietic, Including Myeloma|Hematopoietic Tumor|Neoplasm, Hematopoietic|Hematopoietic Tumors|Hematopoietic and Lymphoid Neoplasms|Hematopoietic Cancer|Hematopoietic Malignancy|Malignancies, Hematopoietic|HEMOLYMPHORETICULAR TUMOR, MALIGNANT|neoplasms hematopoietic|Hematopoietic neoplasm (morphologic abnormality)|Neoplasms, Hematopoietic|Malignant hematopoietic neoplasm (morphologic abnormality)|Malignant hematopoietic neoplasm|Malignant haematopoietic neoplasm|Haematopoietic neoplasm|Hematopoietic malignancy, NOS|hematopoietic cancer | Hematopoietic Neoplasms |
C0079433 | Genes at loci that are involved in the development of WILMS TUMOR. Included are human WT1 at 11p13 and human WT2 (MTACR1) at 11p15. | Tumor Genes, Wilms'|Genes, Wilms|Tumor Genes, Wilms|Wilms Tumor Genes|Genes, Wilm's|Genes, Wilms'|Wilms Genes|Genes, Wilm|Wilms' Tumor Genes|Genes, Wilms' Tumor|Wilms' Genes | Genes, Wilms Tumor |
C0027342 | The thin, horny plates that cover the dorsal surfaces of the distal phalanges of the fingers and toes of primates. | Unguis|Nail plate structure|unguis|nail structure|Nail Plate|NAILS|Nail|nail plate|Nail, NOS|nail|Nail plate structure (body structure)|Nail Apparatus|nail plates|Nails|NAIL|nails|Nail plate | Nail plate |
C0143630 | A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS. | c kit Ligand|Stem Cell Factor|Mast cell growth factor|Steel Factor|SCF|Mast Cell Growth Factor|c-kit Ligand|scf|stem cell factor|mast cell growth factor|stem cell factor (SCF)|MCGF|Kit ligand|kit Ligand | Stem Cell Factor |
C1327099 | The chemical reactions and pathways resulting in the formation of interleukin-1 alpha. [GOC:ai] | interleukin-1 alpha anabolism|interleukin-1 alpha formation|interleukin-1 alpha biosynthesis|interleukin-1 alpha synthesis | interleukin-1 alpha biosynthetic process |
C1327099 | The chemical reactions and pathways resulting in the formation of interleukin-1 alpha. [GOC:ai] | interleukin-1 alpha anabolism|interleukin-1 alpha formation|interleukin-1 alpha biosynthesis|interleukin-1 alpha synthesis | interleukin-1 alpha biosynthetic process |
C1337098 | This gene plays a role in DNA unwinding and recombination-mediated telomere lengthening. | BS|BLM Gene|RECQL3|Bloom Syndrome Gene|BLM RecQ like helicase|DNA HELICASE, RECQ-LIKE, TYPE 2|RECQ PROTEIN-LIKE 3|RECQ2|BLM gene|BLM GENE|BLM | BLM gene |
C1337098 | This gene plays a role in DNA unwinding and recombination-mediated telomere lengthening. | BS|BLM Gene|RECQL3|Bloom Syndrome Gene|BLM RecQ like helicase|DNA HELICASE, RECQ-LIKE, TYPE 2|RECQ PROTEIN-LIKE 3|RECQ2|BLM gene|BLM GENE|BLM | BLM gene |
C0041385 | An N-acetylglycosamine containing antiviral antibiotic obtained from Streptomyces lysosuperificus. It is also active against some bacteria and fungi, because it inhibits the glucosylation of proteins. Tunicamycin is used as tool in the study of microbial biosynthetic mechanisms. | Tunicamycin|tunicamycin | Tunicamycin |
C0027836 | The non-neuronal cells of the nervous system. They not only provide physical support, but also respond to injury, regulate the ionic and chemical composition of the extracellular milieu, participate in the BLOOD-BRAIN BARRIER and BLOOD-RETINAL BARRIER, form the myelin insulation of nervous pathways, guide neuronal migration during development, and exchange metabolites with neurons. Neuroglia have high-affinity transmitter uptake systems, voltage-dependent and transmitter-gated ion channels, and can release transmitters, but their role in signaling (as in many other functions) is unclear. | glial cells|Neuroglial cell|neuroglial cell|Set of glial cells|Glial Cell|Glia (body structure)|Kolliker Reticulum|Glia|neuroglias|Neuroglial cells set|Glial Cells|glial cell|Cell, Glial|Cells, Glial|glia|Set of neuroglial cells|Neuroglial Cell|Glial cell|GLIA|Non-neuronal cell|neuroglia|glial|Neuroglia|Glial|neuroglial cells|Neuroglial Cells|Cell, Neuroglial|Glial cell (cell)|Kolliker's reticulum|Cells, Neuroglial|nerve cement | Neuroglia |
C1113654 | Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA. | nerve stem cell|Cells, Neural Stem|Stem Cells, Neural|Neural Stem Cell|cells nerve stem|Neural stem cell|Stem Cell, Neural|Neural Stem Cells|Cell, Neural Stem|Neural stem cells | Neural Stem Cells |
C0017638 | Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) | Gliomas|glial tumor|Tumor of the Neuroglia|Neuroglial Tumor|Glial Cell Tumors|Tumors, Glial Cell|glial cell tumor|Glial Neoplasm|GLIOMAS|gliomas|GLIOMA|Neoplasm of the Neuroglia|Glioma|Glioma (morphologic abnormality)|Glioma, NOS|glial tumors|Glial Tumor|glioma|Neuroglial Neoplasm|Glial Cell Tumor|Glioma (disorder)|Tumor of Neuroglia|Tumor, Glial Cell|Neoplasm of Neuroglia | Glioma |
C0008976 | Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. | Clinical Trials|Clinical Trial|Clinical Trials as Topic|Clinical Trials, Unspecified|CLINICAL TRIALS|Clinical Trial as Topic|clinical trials|clinical trial|Trial|Clinical trial|Clinical trial (procedure)|Clinical trials | Clinical Trials |
C0220603 | A benign or malignant, primary or metastatic neoplasm of the brain occurring in children. | Brain Neoplasms, Childhood|brain tumor, pediatric|Childhood Neoplasm of the Brain|brain tumor, childhood|Pediatric Brain Neoplasm|brain pediatric tumors|brain childhood tumors|pediatric brain tumor|Pediatric Neoplasm of Brain|Pediatric Brain Tumor|childhood brain tumor|Brain Neoplasm|Brain tumor, child: Other|brain tumor childhood|Childhood Brain Tumor|Pediatric Neoplasm of the Brain|Childhood Brain Tumors|brain tumor pediatric|Pediatric Tumor of the Brain|Childhood Tumor of the Brain|Childhood Neoplasm of Brain|Childhood Tumor of Brain|Pediatric Tumor of Brain|Childhood Brain Neoplasm | Childhood Brain Neoplasm |
C0850397 | null | null | health information |
C0006118 | Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | BRAIN NEOPLASM|Tumor of Brain|Neoplasm, Brain|Neoplasm of brain (disorder)|Brain Tumors|Brain tumors|Brain neoplasm|brain tumours|Brain Tumor|Neoplasm of Brain|Brain tumor|brain tumor|neoplasm of brain|brain tumors|Brain--Tumors|Neoplasms, Brain|brain tumour|Brain Neoplasms|brain cancer|Neoplasm of the Brain|Brain tumour|Tumor, Brain|BRAIN TUMOR|Brain Neoplasm|Tumor of the Brain|BT - Brain tumour|brain neoplasms|Neoplasm of brain|BT - Brain tumor|Neoplasm of unspecified nature of brain|Tumors, Brain|brain neoplasm | Brain Neoplasms |
C0280631 | An aggressive malignant smooth muscle neoplasm, arising from the uterine corpus. It is characterized by a proliferation of neoplastic spindle cells. | Leiomyosarcoma - uterus|leiomyosarcoma uterus|Leiomyosarcoma of Uterus|Uterine Body Leiomyosarcoma|Uterine leiomyosarcoma|leiomyosarcoma, uterine|leiomyosarcomas uterine|Leiomyosarcoma of Uterine Body|Leiomyosarcoma of Uterine Corpus|Body of Uterus Leiomyosarcoma|Leiomyosarcoma of body of uterus|Leiomyosarcoma of corpus uteri|Leiomyosarcoma of the Uterine Corpus|Leiomyosarcoma of uterus (disorder)|Leiomyosarcoma of Corpus Uteri|uterine leiomyosarcoma|Leiomyosarcoma of the Corpus Uteri|Uterine Corpus Leiomyosarcoma|Corpus Uteri Leiomyosarcoma|Leiomyosarcoma of the Uterus|Leiomyosarcoma of the uterus|Leiomyosarcoma of corpus uteri (disorder)|Leiomyosarcoma of Body of Uterus|leiomyosarcoma uterine|UTERUS, LEIOMYOSARCOMA|Leiomyosarcoma of the Uterine Body|uterus leiomyosarcoma|Leiomyosarcoma of the Body of Uterus | Leiomyosarcoma of uterus |
C1135918 | An elongated spindle-shaped contractile cell, peculiar to an involuntary muscle, containing a single nucleus and longitudinally arranged myofibrils. | Myocyte, Smooth Muscle|Smooth muscle tissue cell|Cell, Smooth Muscle|Smooth Muscle Myocytes|Myocyte of smooth muscle|Smooth Muscle Tissue Cell|smooth muscle fiber|Smooth Muscle Cell|Cells, Smooth Muscle|Smooth Muscle Myocyte|smooth muscle fibre|Smooth muscle fiber|Smooth muscle cell|Myocytus nonstriatus|smooth muscle contractile fiber|Non-striated muscle fiber|cells muscle smooth|smooth muscle cell|smooth muscle cells|Leiomyocyte|Smooth Muscle Cells|Smooth muscle myocyte|smooth muscle myocytes | Myocytes, Smooth Muscle |
C1334015 | A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as grade II (moderate dysplasia) or grade III (severe dysplasia). | null | High Grade Intraepithelial Neoplasia |
C1334015 | A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as grade II (moderate dysplasia) or grade III (severe dysplasia). | null | High Grade Intraepithelial Neoplasia |
C0301818 | Hormones possessing the steroid ring system; e.g., androgens, estrogens, adrenocortical hormones. | Steroid hormones|Steroid hormone, NOS|steroid hormone|hormones steroids|Steroid hormone (substance)|hormone steroid|steroid hormones|Steroid Hormone|Steroid hormone|hormones steroid | Steroid hormone |
C0029925 | null | Ovarian carcinoma|OVARIAN CARCINOMA|CARCINOMA OF OVARY | Ovarian Carcinoma |
C1527027 | A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins. | Romidepsin-containing product|L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic|L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-|Romidepsinum|N-[(3S,4E-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) lactone, cyclic|L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide|Product containing romidepsin (medicinal product)|ROMIDEPSIN|L-valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3 -didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-|depsipeptide|romiDEPsin|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic|Depsipeptide|Romidepsina|Romidepsine|Romidepsin (substance)|romidepsin|Romidepsin | romidepsin |
C1527027 | A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins. | Romidepsin-containing product|L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic|L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-|Romidepsinum|N-[(3S,4E-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) lactone, cyclic|L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide|Product containing romidepsin (medicinal product)|ROMIDEPSIN|L-valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3 -didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))-|depsipeptide|romiDEPsin|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic|Depsipeptide|Romidepsina|Romidepsine|Romidepsin (substance)|romidepsin|Romidepsin | romidepsin |
C0025248 | Glycoproteins found on the membrane or surface of cells. | Membrane Glycoprotein|Glycoprotein, Membrane|Surface Glycoproteins, Cell|Glycoprotein, Surface|Cell Surface Glycoprotein|Surface Glycoproteins|Surface Glycoprotein, Cell|Glycoproteins, Membrane|Surface Glycoprotein|Glycoproteins, Surface|Glycoprotein, Cell Surface|Glycoproteins, Cell Surface|membrane glycoprotein|Cell Surface Glycoproteins | Membrane Glycoproteins |
C0036920 | A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells). | Erythroderma, Sezary|Sezary syndrome|Sezary Lymphoma|Sézary's syndrome|sezary syndrome|CTCL / Sezary syndrome|Sezary Syndrome|Sezary's disease|Sézary disease|Sézary's disease (clinical)|sezary's syndrome|Sézary's disease (morphologic abnormality)|Cutaneous T-cell lymphoma/Sezary syndrome|Sezarys Lymphoma|Sézary's disease|Sezary's Lymphoma|sezary's disease|RETICULOSIS SYNDROME, SEZARY|Sezary's syndrome|Syndrome, Sezary|Sézary Syndrome|SEZARY SYNDROME|Sezary's Disease|Sézary's disease (disorder)|Sezary Erythroderma|Lymphoma, Sezary's | Sezary Syndrome |
C0553580 | A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms. | Ewing's Sarcoma|Ewing sarcoma|Ewings Tumor|Ewing's Tumor|ES|sarcoma ewings|sarcoma ewing|Ewing's tumor|SARCOMA, EWING|Sarcoma, Ewings|ewing's sarcoma|Tumor, Ewing's|Ewing Tumor|ewings tumor|Ewing's sarcoma (morphologic abnormality)|EWING TUMOR|Ewing's sarcoma|Ewing Sarcoma|ewings's sarcoma|ewings sarcoma|ewing's tumor|ewings tumors|Tumor, Ewing|Sarcoma, Ewing|sarcoma ewing's|Ewings Sarcoma|ewing sarcoma|EWING SARCOMA|ewing tumor|ewing's tumors|Sarcoma, Ewing's|Ewing's tumour | Ewings sarcoma |
C0011109 | The process of making a selective intellectual judgment when presented with several complex alternatives consisting of several variables, and usually defining a course of action or an idea. | Decision taking|decisionmaking|Making up mind|Decision making (observable entity)|Decision making behaviour|making up mind|Decision making|Decision making behavior|decision making | Decision Making |
C0001580 | Any observable response or action of an adolescent. | Behavior, Adolescent|adolescent behavior|adolescents behavior|Behaviors, Adolescent|Adolescent Behaviors | Adolescent Behavior |
C0020052 | A social unit comprised of one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes. | Household|household|Households|households | Households |
C0346110 | A rare malignant mesothelioma that arises from the pericardium. Clinical presentation includes pericardial effusion, congestive heart failure, a mass or cardiac tamponade. Surgical resection is the treatment of choice. Adjunct treatments of chemotherapy or radiation have not improved outcomes. The prognosis is extremely poor due to its late presentation and difficulty obtaining complete surgical excision. In most cases the diagnosis is made at autopsy or postoperatively. | Malignant Mesothelioma of Pericardium|Malignant mesothelioma of pericardium (disorder)|Pericardial Malignant Mesothelioma|Malignant Mesothelioma of the Pericardium | Malignant mesothelioma of pericardium |
C0191237 | null | Drainage of pericardium|Pericardial aspiration|Drainage of pericardium (procedure)|Pericardial drainage|Decompression of pericardium|Aspiration of pericardium | Drainage of pericardium |
C1260325 | Sarcoma of FOLLICULAR DENDRITIC CELLS most often found in the lymph nodes. This rare neoplasm occurs predominately in adults. | Follicular dendritic cell sarcoma|Follicular Dendritic Cell Sarcoma|Follicular dendritic cell tumour|Follicular Dendritic Cell Sarcoma/Tumor|Follicular dendritic cell tumor|Follicular dendritic cell sarcoma (morphologic abnormality) | Dendritic Cell Sarcoma, Follicular |
C0023928 | Surgery to remove a whole lobe (section) of an organ (such as the lungs, liver, brain, or thyroid gland). | LOBECTOMY|Lobectomy (procedure)|Lobectomy|lobectomy | Lobectomy |
C0205284 | A boundary line or the area immediately inside the boundary. | Marginal|Margin|marginal|Border|Verge|Marginal (qualifier value) | Marginal |
C0449774 | An arrangement of objects, facts, behaviors, or other things which have scientific, mathematical, geometric, statistical, or other meaning. | Pattern (attribute)|pattern|Patterns (qualifier value)|patterns|Pattern | Patterns |
C1273550 | null | Pre-operative chemotherapy (procedure) | Pre-operative chemotherapy |
C0005609 | null | Birth Record|records birth|birth records|Records, Birth|Record, Birth | Birth Records |
C1179132 | Scaffolding Proteins participate in many cellular functions by serving as a supportive base that spatially or temporally organizes, juxtaposes, regulates, and/or promotes the function of other cellular elements (usually proteins). (NCI) | Scaffold protein|Scaffolding Protein | Scaffold protein |
C0006416 | A republic of southeast Asia, northwest of Thailand, long familiar as Burma. Its capital is Yangon, formerly Rangoon. Inhabited by people of Mongolian stock and probably of Tibetan origin, by the 3d century A.D. it was settled by Hindus. The modern Burmese state was founded in the 18th century but was in conflict with the British during the 19th century. Made a crown colony of Great Britain in 1937, it was granted independence in 1947. In 1989 it became Myanmar. The name comes from myanma, meaning the strong, as applied to the Burmese people themselves. (From Webster's New Geographical Dictionary, 1988, p192 & Room, Brewer's Dictionary of Names, 1992, p367) | myanmar|Union of Burma|Myanma|burma|Republic of the Union of Myanmar|Myanmar|Union of Myanmar|MM|MMR|Birma|Burma|MYANMAR|Burma (geographic location)|BURMA | Myanmar |
C1179132 | Scaffolding Proteins participate in many cellular functions by serving as a supportive base that spatially or temporally organizes, juxtaposes, regulates, and/or promotes the function of other cellular elements (usually proteins). (NCI) | Scaffold protein|Scaffolding Protein | Scaffold protein |
C0664336 | An apoptosis inhibitory protein that contains a single baculoviral IAP repeat (BIR) domain. It associates with MICROTUBULES and functions to regulate cell proliferation as a component of the chromosome passage protein complex (CPC), performing essential roles for localization of the complex, chromosome alignment, segregation during MITOSIS and CYTOKINESIS, and assembly of the MITOTIC SPINDLE. It is expressed by fetal kidney and liver cells and highly expressed in ADENOCARCINOMA and high-grade LYMPHOMA. | SRV|Survivin Antigen|Survivin|survivin antigen|survivin|Baculoviral IAP Repeat containing Protein 5|BIRC5 Protein|Baculoviral IAP Repeat-containing Protein 5 | survivin |
C0812581 | null | null | Laparoscopic Procedures on the Ureter |
C0812581 | null | null | Laparoscopic Procedures on the Ureter |
C0069389 | A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41) | oka|Acid, Okadaic|Okadaic acid (substance)|Okadaic acid|Acid, Ocadaic|Ocadaic Acid|okadaic acid|OKA | Okadaic Acid |
C0005025 | null | BENZALKONIUM|Benzalkonium-containing product|Benzalkonium (substance)|Benzalkonium|Product containing benzalkonium (medicinal product)|benzalkonium | benzalkonium |
C0009528 | The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. | Activations, Complement|complement pathway regulation|Activation, Complement|activation complement|Complement Activation|complement cascade|Complement activation|Complement Activations|complement activation|complement response | Complement Activation |
C0019134 | A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. | Eparina|Unfractionated heparin|Heparinic acid|heparin unfractionated|Heparinic Acid|Heparin-containing product|Heparin, Unfractionated|unfractionated heparin|HEPARIN|Heparin (substance)|heparin|Heparinum|Heparin preparation|Product containing heparin (medicinal product)|Heparin|heparins|Unfractionated Heparin|Heparine|Heparina | heparin |
C0014181 | An order of fungi in the phylum Ascomycota that multiply by budding. They include the telomorphic ascomycetous yeasts which are found in a very wide range of habitats. | Yeasts, Budding|Endomycetale|Budding Yeasts|budding yeast|budding yeasts|buds yeast|Saccharomycetales|Budding yeast|Budding Yeast|Budding yeast (organism)|Yeast, Budding|Order Saccharomycetales (organism)|Saccharomycetale|Order Saccharomycetales|Endomycetales | Saccharomycetales |
C0769230 | null | biotin symporter|biotin transporter | biotin transporter |
C0769230 | null | biotin symporter|biotin transporter | biotin transporter |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C0085406 | A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. | Anisotropy|anisotropy|Anisotropies | Anisotropy |
C1333065 | A rare benign lung tumor with perivascular epithelioid cell differentiation. It is composed of round or oval cells with abundant clear or eosinophilic cytoplasm and distinct cell borders. The vast majority of patients are asymptomatic and the tumors are discovered incidentally. Excision is curative. | CCSTL|Clear Cell-Sugar-Tumor of Lung|Clear Cell-Sugar-Tumor of the Lung|Sugar Tumor | Lung Clear Cell Tumor |
C1333065 | A rare benign lung tumor with perivascular epithelioid cell differentiation. It is composed of round or oval cells with abundant clear or eosinophilic cytoplasm and distinct cell borders. The vast majority of patients are asymptomatic and the tumors are discovered incidentally. Excision is curative. | CCSTL|Clear Cell-Sugar-Tumor of Lung|Clear Cell-Sugar-Tumor of the Lung|Sugar Tumor | Lung Clear Cell Tumor |
C0009375 | Tumors or cancer of the COLON. | Colonic mass|colon tumor cancer|colonic neoplasm|Colon tumor|NEOPLASM OF COLON|Neoplasm, Colon|Neoplasm of Colon|colon cancer tumor|Tumor of Colon|colon neoplasm|colon masses|cancer colon tumors|Neoplasms, Colonic|Neoplasm of the Colon|colonic neoplasms|Colonic Tumor|Colon Tumor|Colon Neoplasm|Tumor of colon|Colonic Neoplasms|Neoplasms, Colon|neoplasm of colon|colon mass|colon tumours|Neoplasm of colon|Colonic tumor|Colonic Neoplasm|Tumor of the Colon|colon tumors|COLONIC NEOPLASM|colonic mass|colon tumor|Colon Neoplasms|Tumour of colon|colon neoplasms|COLON TUMOR|Neoplasm of the colon|colon tumor or cancer|Neoplasm of colon (disorder)|Neoplasm, Colonic|tumor colon | Colonic Neoplasms |
C1098841 | null | null | epiprocurcumenol |
C1098841 | null | null | epiprocurcumenol |
C0006521 | Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. | butyrate|Butyrates | Butyrates |
C0293866 | null | null | syntrophin |
C0006945 | A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS. | 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium Chloride|Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride|carbacol|Carbachol (substance)|Carbamylcholine chloride|carbachol|carbacholine|CARBACHOL|Carbachol|Carbocholine|Carbamoylcholine chloride|Carbachol-containing product|Carbacholine|Product containing carbachol (medicinal product)|Choline carbamate | carbachol |
C0063245 | null | N(6)-(4-amino-2-hydroxybutyl)-L-lysine|(R)-N6-(4-amino-2-hydroxybutyl)-L-lysine|(+)-hypusine | hypusine |
C0870454 | null | dyad | dyads |
C0003589 | The protein components of enzyme complexes (HOLOENZYMES). An apoenzyme is the holoenzyme minus any cofactors (ENZYME COFACTORS) or prosthetic groups required for the enzymatic function. | apoenzyme|Apoenzyme | Apoenzymes |
C0027270 | A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed) | nicotinamide-adenine dinucleotide|Nicotinamide-Adenine Dinucleotide|nad|nadide|Coenzyme I|Adenine Dinucleotide, Dihydronicotinamide|NAD|Adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt|Adenosine 5'-(Trihydrogen Diphosphate), 5'-5'-Ester with 3-(Aminocarbonyl)-1-Beta-D-Ribofuranosylpyridinium, Hydroxide, Inner Salt|NAD+|nicotinamide adenine dinucleotide (NAD)|3-Carbamoyl-1-Beta-D-Ribofuranosylpyridinium Hydroxide 5'-5'-Ester with Adenosine 5'-(Trihydrogen Pyrophosphate) Inner Salt|Diphosphopyridine Nucleotide|DPN|Nicotinamide adenine dinucleotide (substance)|Dihydronicotinamide Adenine Dinucleotide|Codehydrogenase I|Nucleotide, Diphosphopyridine|nicotinamide adenine dinucleotide|Nicotinamide Adenine Dinucleotide|Dinucleotide, Nicotinamide-Adenine|Nicotinamide adenine dinucleotide|Dinucleotide, Dihydronicotinamide Adenine|Beta-NAD|Nadide|NADIDE|Nicotinamide adenine dinucleotide (NAD)|dihydronicotinamide adenine dinucleotide|Cozymase|3-Carbamoyl-1-Beta-D-Ribofuranosylpyridinium Hydroxide, 5'-Ester with Adenosine 5'-Pyrophosphate, Inner Salt|Co-I | nicotinamide adenine dinucleotide (NAD) |
C0034790 | Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. | Receptors, T-Cell|T cells--Receptors|T-Cell Antigen Receptors|Major Histocompatibility Complex Receptor|T-Cell Receptors|T cell receptor|t-cell receptor|Receptors, T Cell Antigen|Receptors, T-Cell Antigen|T-cell antigen receptor site|MHC Receptor|T Cell Receptor|T Cell Antigen Receptor|Antigen Receptors, T-Cell|Receptors, Antigen, T-Cell|t-cell receptor (TCR)|T-cell antigen receptor (substance)|Antigen Receptors, T Cell|T-Cell Receptor|T-cell antigen receptor|t cell receptors|t cell receptor|Antigen Receptor, T-Cell|T-Cell Antigen Receptor|TCR|tcr|Receptor, T-Cell Antigen|Receptor, T-Cell|T Cell Receptors | T-Cell Receptor |
C0218111 | null | dihydropyridine receptor|Dihydropyridine receptor|L Type VDCC alpha 1 Subunit|Receptor, Dihydropyridine|L-Type VDCC alpha-1 Subunit|Dihydropyridine Receptors|Dihydropyridine Receptor | Receptors, Dihydropyridine |
C0218111 | null | dihydropyridine receptor|Dihydropyridine receptor|L Type VDCC alpha 1 Subunit|Receptor, Dihydropyridine|L-Type VDCC alpha-1 Subunit|Dihydropyridine Receptors|Dihydropyridine Receptor | Receptors, Dihydropyridine |
C1155065 | The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific. [GOC:mgi_curators, ISBN:0781735149] | T lymphocyte activation|T cell activation|T-lymphocyte activation|T-cell activation | T-Cell Activation |
C0600431 | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] | calcium-mediated signalling|Calcium Signaling|Calcium Ion Signaling|Calcium Signalings|calcium signaling|calcium-mediated signaling|calcium ion signaling|Signalings, Calcium|calcium signalling|Signaling, Calcium | Calcium Signaling |
C0050652 | null | null | actinonin |
C0053355 | A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity. | [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine|UBENIMEX|ubenimex|Bestatin|L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, [S-(R*,S*)]-|Ubenimex|bestatin|Ubenimexum|3-amino-2-hydroxy-4-phenylbutyryl-L-leucine|[S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine|(3-amino-2-hydroxy-4-phenylbutanoyl)-L-leucine|N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine | ubenimex |
C0205117 | Next to or adjoining. | next|Juxta-posed (qualifier value)|Adjacent|Juxta-|Next to|adjacent to|adjacent|next to|Adjacent to|Juxta-posed | Adjacent |
C0025831 | A subclass of enzymes of the transferase class that catalyze the transfer of a methyl group from one compound to another. (Dorland, 28th ed) EC 2.1.1. | methyltransferases|methyltransferase|transmethylase|Methyltransferases|methylase|Methyltransferase|Substance with methyltransferase mechanism of action|Substance with methyltransferase mechanism of action (substance)|EC 2.1.1 | Methyltransferase |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.